Vitamin B3 supplement for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of early Alzheimer's disease or mild cognitive impairment due to Alzheimer's within the last 2 years.
- You need to have evidence of Alzheimer's changes in your brain, confirmed by a spinal fluid test or a PET scan.
- You must be between 50 and 85 years old.
- You need to have a recent memory test score that shows you are able to give informed consent (MoCA ≥ 16 or MMSE ≥ 20).
- You must have a study partner (like a family member or friend) who can support you and help with study tasks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a natural substance called NAD can improve brain health in people with early Alzheimer's. You may be eligible if you have a firm Alzheimer's diagnosis, are between 65 and 80, and can walk and talk without help.
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
This trial is testing whether a form of vitamin B3 (called NAD) can help prevent or slow down Alzheimer's disease in people with Down syndrome. The goal is to see if this supplement can protect brain cells and improve memory or thinking.
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
This trial tests whether a supplement called Neuroaid II can help people with mild to moderate Alzheimer's disease. It is a pill taken alongside your usual Alzheimer's treatments, and the study aims to see if it can slow down memory decline.
This trial studies whether taking an NAD supplement can support brain blood vessel health as people age. Participants will be tested for brain and health changes and may help researchers understand how to keep the brain’s blood vessels healthier over time.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.